Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesWuhan BioRaid Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan BioRaid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A